Roche’s fenebrutinib shows unprecedented positive phase III results as the potential first and only BTK inhibitor in both relapsing and primary progressive multiple sclerosis ...

Happy Tuesday! SoftBanks Sumer Juneja discussed the funds India strategy, Lenskarts public listing, and more in an exclusive ...

The demand for experienced professionals is far outpacing supply, with firms aggressively poaching from banks, brokerages and ...

A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at ABOUT TG THERAPEUTICS TG Therapeutics is a fully ...

Roche Holding (OTC: RHHBY) stock jumped 3.4% through 1:05 p.m. ET Monday after the pharmaceutical giant's Genentech subsidiary announced positive phase 3 clinical trial results for its fenebrutinib ...

GovHost, a leading provider of public safety software solutions, today announced its acquisition of True North Software LLC, an Illinois-based company known for its cloud-native Computer-Aided ...

Findings showed fenebrutinib significantly reduced relapses vs teriflunomide in RMS and was noninferior to ocrelizumab in slowing disability progression in PPMS. Topline data were announced from two ...

From America's richest man to one of the world's first film stars, some of the world’s richest people were lost to the waves, ...

Roche (RHHBY) stock gains and TG Therapeutics (TGTX) stock falls as the Swiss firm's new drug for multiple sclerosis succeeds in two late-stage trials. Read more here.

May 7th, 1915. The RMS Lusitania sliced through calm Atlantic waters, unaware that German U-boat U-20 was waiting. When a ...